What Happened?
, -based Selecta Biosciences Appointed Blaine Davis as Chief Financial Officer
Date of management change: November 28, 2022
, -based Selecta Biosciences Appointed Blaine Davis as Chief Financial Officer
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by avoiding unwanted immune responses. Selecta`s tolerogenic Synthetic Vaccine Particles (SVP™) technology platform is designed to enable a range of novel biologics for rare and serious diseases that require new treatment options. The company`s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company`s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta`s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts.
Blaine Davis is Chief Financial Officer at Selecta Biosciences. Previously, Blaine held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Brandt Maura, Chamberlain Karen, Griesse Daniel, Warrington Parker Wendy, Cook Jennifer, Srivastava Swati, Grizzel Steve, Johnson Theresa, Luongo Laurie, Hamilton Lisa, Wenokur Justin
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.